ONCAlert | 2018 ASCO Annual Meeting

An Overview of the MERIBEL Study in HER2-Negative Breast Cancer

Antonio Llombart-Cussac, MD, PhD
Published Online: 4:14 PM, Thu October 13, 2016


Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study during an interview at the 2016 ESMO Congress. The study assessed first-line eribulin (Halaven) for taxane-resistant patients with HER2-negative metastatic breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.